Management of immune checkpoint inhibitor-associated myocarditis: An overview

· The researchers observed that the clinical presentation and cardiac pathological findings are greatly variable in patients with ICI-associated myocarditis.

· And though endomyocardial biopsy is a standard diagnostic test, a combination of clinical suspicion, cardiac biomarkers (specifically troponin), and cardiac imaging, in addition to a biopsy are generally required to support the diagnosis.

· Lastly, the combination of a cytotoxic T-lymphocyte-associated protein 4 inhibitors with a programmed cell death protein 1 or programmed death-ligand 1 inhibitor increases the risk of developing ICI-associated myocarditis.

The researchers concluded that a complete history of recent cancer treatments and physical examination in combination with cardiac biomarkers, cardiac imaging, and endomyocardial biopsy represent a pragmatic diagnostic approach for most cases of ICI-associated myocarditis. Also, the addition of novel biomarkers or imaging modalities is an area of active research and should be evaluated within the larger cohorts.

Reference:

 A study titled, "Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis: A Narrative Review" by Lehmann L et. al published in the JAMA Cardiol.

DOI:10.1001/jamacardio.2021.2241